Effects of Pitavastatin on Lipid Profiles and High-Sensitivity CRP in Japanese Subjects with Hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) Investigatars

Koshiyama, Hiroyuki; Taniguchi, Ataru; Tanaka, Kiyoshi; Kagimoto, Shinji; Fujioka, Yoshio; Hirata, Ken‐ichi; Nakamura, Yoshio; Iwakura, Akane; Hara, Kyoko; Yamamoto, T.; Kuroe, Akira; Ohya, Masaki; Fujimoto, Shimpei; Hamamoto, Yoshiyuki; Honjo, Sachiko; Ikeda, Hiroki; Nabe, Koichiro; Tsuda, Kinsuke; Inagaki, Nobuya; Seino, Yutaka; Kume, Noriaki

doi:10.5551/jat.e581

Cited by 42 publications

(46 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An in vitro study demonstrated that pitavastatin inhibited RLP-induced macrophage foam cell formation, at least in part through regulation of the apoB48 receptor expression, a novel receptor for RLPs 16) . A recent study by Koshiyama et al showed that the administration of pitavastatin significantly reduced serum remnant-like particle cholesterol (RLP-C) levels by 22.8%, together with serum LDL and hs-CRP levels 17) , which suggested that pitavastatin improved lipid profiles and prevented atherogenic changes.…”

Section: Discussionmentioning

confidence: 99%

Pitavastatin Improves Plasma Pentraxin 3 and Arterial Stiffness in Atherosclerotic Patients with Hypercholesterolemia

Ohbayashi

Miyazawa

Miyamoto

et al. 2009

JAT

View full text Add to dashboard Cite

Objective: To investigate the effect of pitavastatin on asymptomatic atherosclerosis in patients with hypercholesterolemia. Methods: Thirty-five outpatients with hypercholesterolemia (61.5 12.8 yr) were administered 2 mg oral pitavastatin daily for 6 months. Plasma pentraxin 3 (PTX3), a novel inflammatory marker of atherosclerosis, was measured together with the serum hsCRP and carotid-artery intima-media thickness (IMT). Results: Significant improvement of the LDL-C/HDL-C and log (TG/HDL-C) ratios began to be observed from 1 month after using pitavastatin. Significant correlation of the initial PTX3 value was observed with the initial plaque score (PS) (p 0.038, r 0.246), but not between the hsCRP and plasma PTX3 or PS. When patients were divided into 3 groups based on the initial PTX3 values, a significant decrease of the plasma PTX3 was obtained in the highest PTX3 group alone (p 0.034). The change in the plasma PTX3 value ( PTX3) was significantly correlated with the mean IMT during the study period (p 0.008, r 0.456). Conclusion: Pitavastatin significantly reduced the elevated plasma levels of PTX3 in patients with hypercholesterolemia by its pleiotropic effect against atherosclerotic inflammation. This study showed for the first time that the plasma PTX3 might be a useful blood parameter for direct detection of active atherosclerotic change.

show abstract

Section: Discussionmentioning

confidence: 99%

Pitavastatin Improves Plasma Pentraxin 3 and Arterial Stiffness in Atherosclerotic Patients with Hypercholesterolemia

Ohbayashi

Miyazawa

Miyamoto

et al. 2009

JAT

View full text Add to dashboard Cite

show abstract

“…Finally, in our study, 39% of patients were taking statins. Because hsCRP levels were reported to be affected by the use of statins [31][32][33] , the inclusion of patients who were taking statins may have confounded the results of the correlations between hsCRP levels and coronary or aortic atherosclerosis; however, now that statin use in patients with CAD is very common, the exclusion of patients taking statins would render our results inapplicable to general patients with CAD.…”

Section: )mentioning

confidence: 94%

Associations Between Plasma C-reactive Protein Levels and the Severities of Coronary and Aortic Atherosclerosis

Momiyama¹,

Ohmori²,

Fayad³

et al. 2010

JAT

View full text Add to dashboard Cite

Aim:Limited correlations between C-reactive protein (CRP) and coronary artery disease (CAD) have been reported. Recently, MRI became a useful tool for non-invasively evaluating atherosclerotic plaques in thoracic and abdominal aortas. Methods: To elucidate the associations between plasma CRP levels and the severities of coronary and aortic atherosclerosis, we performed aortic black-blood MRI in 136 patients undergoing coronary angiography. For each patient, 9 slices of thoracic aorta and 9 slices of abdominal aorta were obtained at 12-mm intervals, and the plaque extent in each slice was scored. The degree of aortic atherosclerosis is represented as the sum of scores. The degree of coronary atherosclerosis is represented as the number of 50% stenotic vessels and 25% stenotic segments.

show abstract

“…In two cases, pitavastatin was suggested to improve not only LDL-C and HDL-C, but also HOMA-IR and GIR. Pitavastatin has pleiotropic effects which do not depend on lipid diminishing actions such as the anti-inflammatory effect [9], antioxidant effect [10] and endothelial function improvement [11]. In addition, it has been confirmed that pitavastatin increases adiponectin in hypercholesterolemic and patients with type 2 diabetes [12], and these actions may contribute to the amelioration of insulin resistance.…”

Section: Discussionmentioning

confidence: 97%

Pitavastatin Ameliorates Insulin Resistance in Type 2 Diabetic Patients: Report of Two Cases

Satoh¹,

Kudoh²,

Hikita³

et al. 2012

J Diabetes Metab

View full text Add to dashboard Cite

Introduction: Statins reduce cardiovascular risk in populations targeted for both primary and secondary prevention. The potential of statin use to impact the risk of developing new onset diabetes has been suggested. However, there have been a few large-scale RCTs of pitavastatin which is the statin, but adverse effects on glucose metabolism and diabetes onset were not documented by meta analysis.Case reports: We report two patients with type 2 diabetes and hypercholesterolemia showing amelioration of insulin resistance with pitavastatin. The improvements were attributed to effects of pitavastatin on glucose and insulin metabolism. A 75-year-old man and a 70-year-old woman with type 2 diabetes, hypercholesterolemia and hypertension were given pitavastatin (2 mg/day) for 6 months, without changes in other medication. Before and after treatment, both received euglycemic hyperinsulinemic clamp studies to assess insulin sensitivity. After 6 months, glucose infusion rates were increased in both subjects. Conclusion:These cases suggest that pitavastatin, unlike other statins, has beneficial effects on insulin sensitivity in an insulin-resistant state.

show abstract

Effects of Pitavastatin on Lipid Profiles and High-Sensitivity CRP in Japanese Subjects with Hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) Investigatars

Cited by 42 publications

References 27 publications

Pitavastatin Improves Plasma Pentraxin 3 and Arterial Stiffness in Atherosclerotic Patients with Hypercholesterolemia

Pitavastatin Improves Plasma Pentraxin 3 and Arterial Stiffness in Atherosclerotic Patients with Hypercholesterolemia

Associations Between Plasma C-reactive Protein Levels and the Severities of Coronary and Aortic Atherosclerosis

Pitavastatin Ameliorates Insulin Resistance in Type 2 Diabetic Patients: Report of Two Cases

Contact Info

Product

Resources

About